JP5893037B2 - Brafv600eに特異的に結合する抗体を使用する癌の診断のための手段及び方法 - Google Patents
Brafv600eに特異的に結合する抗体を使用する癌の診断のための手段及び方法 Download PDFInfo
- Publication number
- JP5893037B2 JP5893037B2 JP2013530750A JP2013530750A JP5893037B2 JP 5893037 B2 JP5893037 B2 JP 5893037B2 JP 2013530750 A JP2013530750 A JP 2013530750A JP 2013530750 A JP2013530750 A JP 2013530750A JP 5893037 B2 JP5893037 B2 JP 5893037B2
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cancer
- braf
- sample
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 112
- 201000011510 cancer Diseases 0.000 title claims description 92
- 238000000034 method Methods 0.000 title claims description 65
- 238000003745 diagnosis Methods 0.000 title claims description 20
- 210000004027 cell Anatomy 0.000 claims description 41
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 38
- 230000027455 binding Effects 0.000 claims description 28
- 238000004458 analytical method Methods 0.000 claims description 25
- 210000004408 hybridoma Anatomy 0.000 claims description 17
- 238000011319 anticancer therapy Methods 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 230000009870 specific binding Effects 0.000 claims description 8
- 238000011156 evaluation Methods 0.000 claims description 7
- 229960005395 cetuximab Drugs 0.000 claims description 4
- YABJJWZLRMPFSI-UHFFFAOYSA-N 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-2-benzimidazolamine Chemical compound N=1C2=CC(OC=3C=C(N=CC=3)C=3NC(=CN=3)C(F)(F)F)=CC=C2N(C)C=1NC1=CC=C(C(F)(F)F)C=C1 YABJJWZLRMPFSI-UHFFFAOYSA-N 0.000 claims description 3
- 108020005544 Antisense RNA Proteins 0.000 claims description 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 3
- 238000009007 Diagnostic Kit Methods 0.000 claims description 3
- DEZZLWQELQORIU-RELWKKBWSA-N GDC-0879 Chemical compound N=1N(CCO)C=C(C=2C=C3CCC(/C3=CC=2)=N\O)C=1C1=CC=NC=C1 DEZZLWQELQORIU-RELWKKBWSA-N 0.000 claims description 3
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 3
- 108020004459 Small interfering RNA Proteins 0.000 claims description 3
- -1 anti-BRAF antibody Substances 0.000 claims description 3
- 239000003184 complementary RNA Substances 0.000 claims description 3
- 229960003787 sorafenib Drugs 0.000 claims description 3
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims description 3
- 229960003862 vemurafenib Drugs 0.000 claims description 3
- 102200055464 rs113488022 Human genes 0.000 description 60
- 210000001519 tissue Anatomy 0.000 description 54
- 108090000765 processed proteins & peptides Proteins 0.000 description 37
- 102000004196 processed proteins & peptides Human genes 0.000 description 25
- 230000035772 mutation Effects 0.000 description 23
- 229920001184 polypeptide Polymers 0.000 description 23
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 18
- 201000009277 hairy cell leukemia Diseases 0.000 description 14
- 238000001514 detection method Methods 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 238000001262 western blot Methods 0.000 description 9
- 230000002163 immunogen Effects 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 201000001441 melanoma Diseases 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 238000001574 biopsy Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 108700020796 Oncogene Proteins 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 238000003364 immunohistochemistry Methods 0.000 description 6
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 206010025323 Lymphomas Diseases 0.000 description 5
- 101100381978 Mus musculus Braf gene Proteins 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 210000001185 bone marrow Anatomy 0.000 description 5
- 238000011144 upstream manufacturing Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 238000001712 DNA sequencing Methods 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000012744 immunostaining Methods 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- 238000007400 DNA extraction Methods 0.000 description 3
- 102000001301 EGF receptor Human genes 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 206010064912 Malignant transformation Diseases 0.000 description 2
- 241000713862 Moloney murine sarcoma virus Species 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 238000012197 amplification kit Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 102000050152 human BRAF Human genes 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000036212 malign transformation Effects 0.000 description 2
- 210000003519 mature b lymphocyte Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 101000800130 Bos taurus Thyroglobulin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101100381977 Homo sapiens BRAF gene Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 201000003791 MALT lymphoma Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100467524 Murine sarcoma virus 3611 V-RAF gene Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- XDJOONDGQPHXMW-UHFFFAOYSA-J [Tc+4].[I-].[I-].[I-].[I-] Chemical compound [Tc+4].[I-].[I-].[I-].[I-] XDJOONDGQPHXMW-UHFFFAOYSA-J 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 108091005948 blue fluorescent proteins Proteins 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000005081 chemiluminescent agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000012303 cytoplasmic staining Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004851 dishwashing Methods 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011273 incision biopsy Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 1
- 208000021937 marginal zone lymphoma Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002324 minimally invasive surgery Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 201000006845 reticulosarcoma Diseases 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 208000013076 thyroid tumor Diseases 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
a)BRAFポリペプチドにおいて配列番号:1により特徴付けられるエピトープに特異的に結合する抗体に該サンプルを、該抗体のエピトープへの結合を可能にする条件下で接触させ、
b)エピトープに対する抗体の結合を決定し、それによって癌が診断される、
ことを含む方法に関する。
a)本発明の抗体を含む分析ユニットであって、該分析ユニットに適用されるサンプル中のBRAFポリペプチドにおいて配列番号:1により特徴付けられるエピトープへの抗体の特異的結合の決定を可能にする分析ユニットと;
b)分析ユニットにより決定される結合を評価し、診断を確立するための実行ルールを含む評価ユニット
を含む癌の診断装置に関する。
a)B-Rafポリペプチドにおいて配列番号:1により特徴付けられるエピトープに特異的に結合する抗体に該サンプルを、該抗体のエピトープへの結合を可能にする条件下で接触させ、
b)エピトープに対する抗体の結合を決定し、それによって癌が診断される、
ことを含む方法に関する。
a)上で言及された本発明の抗体を含む分析ユニットであって、分析ユニットに適用されるサンプル中のBRAFポリペプチドにおいて配列番号:1により特徴付けられるエピトープに対する前記抗体の特異的結合の決定を可能にする分析ユニットと;
b)分析ユニットにより決定される結合を評価し、診断を確立する実行ルールを含む評価ユニット
を含む癌診断装置にさらに関する。
596から606位のBRAFアミノ酸配列に適合し、V->E交換を抱える合成ペプチドGLATEKSRWSG(配列番号:1)を商業的に産生させた。Husarソフトウェアパッケージ(DKFZ, Heidelberg, Germany)を、適切な配列領域を選択するために使用した。ペプチドをKLH(キーホールリンペットへモシアニン)にコンジュゲートさせ、免疫原性ペプチドを形成させた。6週齢の雌のC57black sexマウス(Charles River, Sulzfeld, Germany)を使用した。常に、100μl容量を次のスケジュールに従い、マウスの後肢に注射した:
1日目:完全フロイントアジュバントを用い、1:1であることが明らかなPBSに溶解した20μgの免疫原性ペプチドを、マウスに注射した。
5日目:不完全フロイントアジュバントを用い、1:1であることが明らかなPBSに溶解した20μgの免疫原性ペプチドを、マウスに注射した。
11日目:PBSに溶解した20μgの免疫原性ペプチドを、マウスに注射した。
18日目:PBSに溶解した20μgの免疫原性ペプチドを、マウスに注射した。
ホルマリン固定されパラフィン包埋された切片を、電気冷却対物クランプ(クールカット(Cool-Cut)TM;Thermo Fisher Scientific)を具備したミクロムHM355CTMミクロトーム(Thermo Fisher Scientific,Waltham, MA, USA)を用いて4μmに切断した。その後、切片を80℃で15分乾燥させ、ベンタナベンチマーク(Ventana BenchMark)XT(登録商標)免疫染色器(Ventana Medical Systems, Tucson, AZ, USA)で抗BRAF V600E抗体(クローン263)を染色した。ベンタナ染色手順は、60分、細胞コンディショナー1(pH8)を用いた前処理を含み、ついで、37℃で32分、希釈しないBRAF V600Eハイブリドーマ上清と共にインキュベートした。抗体のインキュベートに続いて、ベンタナ増幅キット、ウルトラウォッシュ(UltraWash)を含むベンタナ標準シグナル増幅をし、1滴のヘマトキシリンで4分、1滴の青化試薬で4分、対比染色させた。発色検出のために、ウルトラビュー(ultraView)TMユニバーサルレッドv3検出キット(Ventana Medical Systems)を使用した。続いて、免疫染色器からスライドを取り除き、皿洗い用洗浄剤を用いて水で洗浄し、取り付けた。一次抗体BRAF V600E(クローン263)を取り除いても、色素原は検出されなかった。腫瘍細胞がBRAF V600Eに対して強い細胞質染色を示した場合に、免疫反応はポジティブであるとスコアリングされた。弱い拡散染色及びマクロファージの染色は、ポジティブとスコアリングされなかった。
全てのヒトの材料は、National Center for Tumor Diseases (NCT) and the Department of General Pathology, Institute for Pathology, HeidelbergのTissue Bankから得た。形質細胞腫 (n=26)、濾胞性リンパ腫(n=34)、びまん性大細胞型B細胞リンパ腫(n=41)、縦隔原発B細胞性大細胞型リンパ腫(n=25)、マントル細胞リンパ腫(n=17)、節外周辺帯B細胞リンパ腫(n=16)、ヘアリー細胞リンパ腫(n=3)及びホジキンリンパ腫(n=46)を含む成熟B細胞腫瘍の208の症例を含むパラフィン包埋組織から構築された組織マイクロアレイ(TMA)を分析した。さらなる実験のために、ヘアリー細胞白血病(全n=35)を有する骨髄(n=34)又は脾臓(n=1)、及び脾臓周辺帯リンパ腫(SMZL)(n=4)を有する骨髄からの付加的な完全切片を評価した。
Claims (11)
- 癌に罹患している疑いのある被験者のサンプルにおいて癌細胞の有無を決定する方法であって、
a)BRAFポリペプチドにおいて配列番号:1により特徴付けられるエピトープに特異的に結合する抗体に該サンプルを、該抗体のエピトープへの結合を可能にする条件下で接触させ、
b)エピトープに対する抗体の結合を決定し、それによって癌細胞の有無が決定される
ことを含み、
前記抗体が受託番号DSM ACC3091で寄託されているハイブリドーマクローンにより生成された抗体である、方法。 - 前記癌細胞が組織サンプル内に存在する請求項1に記載の方法。
- 前記組織サンプルが組織切片サンプルである請求項2に記載の方法。
- 工程b)における抗体のエピトープへの結合が、被験者が抗癌療法に応答性であることを示す、請求項1に記載の方法。
- 前記抗癌療法が、抗BRAFアンチセンスRNA、siRNA又はミクロRNA剤、抗BRAF抗体、ソラフェニブ、RAF-265、PLX-4032、セツキシマブ、及びGDC-0879からなる群から選択される請求項4に記載の方法。
- 受託番号DSM ACC3091で寄託されているハイブリドーマクローンにより生成された抗体。
- 受託番号DSM ACC3091で寄託されているハイブリドーマクローン。
- a)請求項6に記載の抗体を含む分析ユニットであって、該分析ユニットに適用されるサンプル中のBRAFポリペプチドにおいて配列番号:1により特徴付けられるエピトープへの抗体の特異的結合の決定を可能にする分析ユニットと;
b)分析ユニットにより決定される結合を評価し、診断を確立するための実行ルールを含む評価ユニット
を含む癌の診断装置。 - 前記サンプルが組織サンプルである請求項8に記載の装置。
- 前記組織サンプルが組織切片サンプルである請求項9に記載の装置。
- 請求項6に記載の抗体を含む癌診断キット。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38815810P | 2010-09-30 | 2010-09-30 | |
US61/388,158 | 2010-09-30 | ||
US201161503950P | 2011-07-01 | 2011-07-01 | |
US61/503,950 | 2011-07-01 | ||
PCT/EP2011/067092 WO2012042009A1 (en) | 2010-09-30 | 2011-09-30 | Means and methods for diagnosing cancer using an antibody which specifically binds to braf v600e |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013543117A JP2013543117A (ja) | 2013-11-28 |
JP2013543117A5 JP2013543117A5 (ja) | 2015-10-01 |
JP5893037B2 true JP5893037B2 (ja) | 2016-03-23 |
Family
ID=44789447
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013530750A Active JP5893037B2 (ja) | 2010-09-30 | 2011-09-30 | Brafv600eに特異的に結合する抗体を使用する癌の診断のための手段及び方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US9297812B2 (ja) |
EP (1) | EP2622348B1 (ja) |
JP (1) | JP5893037B2 (ja) |
CN (1) | CN103403550B (ja) |
AU (1) | AU2011310096B2 (ja) |
CA (1) | CA2813098C (ja) |
DK (1) | DK2622348T3 (ja) |
ES (1) | ES2554678T3 (ja) |
WO (1) | WO2012042009A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103172744B (zh) * | 2012-09-28 | 2016-01-13 | 武汉纽斯特生物技术有限公司 | 特异性识别B-Raf突变蛋白的单克隆抗体、制备方法及其应用 |
JP6485854B2 (ja) * | 2014-09-24 | 2019-03-20 | 国立研究開発法人国立循環器病研究センター | 抗変異型プロテインs抗体、該抗体を含む診断用組成物、変異型ヒトプロテインsの検出方法および該抗体を含むキット |
CA3049926A1 (en) | 2017-01-17 | 2018-07-26 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
JP6941688B2 (ja) * | 2017-06-29 | 2021-09-29 | コリア アドヴァンスド インスティテュート オブ サイエンス アンド テクノロジー | 神経節膠腫が誘導された動物モデルならびに神経節膠腫およびこれに関連する疾患の診断用組成物 |
CN110183535A (zh) * | 2018-12-17 | 2019-08-30 | 南京基诺米医疗科技有限公司 | 鼠抗人braf v600e突变蛋白单克隆抗体制备及其免疫组化用途 |
CN111285935B (zh) * | 2020-05-13 | 2020-09-11 | 方达医药技术(上海)有限公司 | 特异性检测braf基因突变的抗体及其在制备癌症检测试剂盒中的用途 |
AU2021378815A1 (en) * | 2020-11-16 | 2023-06-29 | Agilent Technologies, Inc. | Chimeric anti-human braf v600e antibodies and methods for making and using them |
WO2024090265A1 (ja) * | 2022-10-28 | 2024-05-02 | 株式会社biomy | 情報処理装置、情報処理方法及びプログラム |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6735531B2 (en) * | 1996-10-07 | 2004-05-11 | Lab Vision Corporation | Method and apparatus for automatic tissue staining |
WO2005047542A1 (en) * | 2003-10-16 | 2005-05-26 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Treatments for inhibiting development and progression of nevi and melanoma having braf mutations |
WO2007002811A2 (en) | 2005-06-29 | 2007-01-04 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for treating melanoma |
WO2009036188A2 (en) | 2007-09-11 | 2009-03-19 | University Of Massachusetts | Insulin-like growth factor binding protein 7 for treatment of cancer |
CA2639416C (en) | 2007-09-11 | 2019-12-31 | F. Hoffmann-La Roche Ag | Diagnostic test for susceptibility to b-raf kinase inhibitors |
-
2011
- 2011-09-30 CN CN201180056079.4A patent/CN103403550B/zh active Active
- 2011-09-30 EP EP11767970.4A patent/EP2622348B1/en active Active
- 2011-09-30 WO PCT/EP2011/067092 patent/WO2012042009A1/en active Application Filing
- 2011-09-30 US US13/877,035 patent/US9297812B2/en active Active
- 2011-09-30 CA CA2813098A patent/CA2813098C/en active Active
- 2011-09-30 ES ES11767970.4T patent/ES2554678T3/es active Active
- 2011-09-30 AU AU2011310096A patent/AU2011310096B2/en active Active
- 2011-09-30 JP JP2013530750A patent/JP5893037B2/ja active Active
- 2011-09-30 DK DK11767970.4T patent/DK2622348T3/en active
Also Published As
Publication number | Publication date |
---|---|
CA2813098C (en) | 2019-10-08 |
JP2013543117A (ja) | 2013-11-28 |
AU2011310096A1 (en) | 2013-04-18 |
US20130266962A1 (en) | 2013-10-10 |
DK2622348T3 (en) | 2015-12-14 |
EP2622348B1 (en) | 2015-09-16 |
EP2622348A1 (en) | 2013-08-07 |
WO2012042009A1 (en) | 2012-04-05 |
CN103403550B (zh) | 2015-08-19 |
CN103403550A (zh) | 2013-11-20 |
US9297812B2 (en) | 2016-03-29 |
ES2554678T3 (es) | 2015-12-22 |
CA2813098A1 (en) | 2012-04-05 |
AU2011310096B2 (en) | 2014-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5893037B2 (ja) | Brafv600eに特異的に結合する抗体を使用する癌の診断のための手段及び方法 | |
US10273308B2 (en) | Methods of producing antibodies specific for p95 | |
EP2494359B1 (en) | Podxl protein in colorectal cancer | |
WO2012141285A1 (ja) | 乳癌のバイオマーカー | |
US20190154694A1 (en) | Detection and treatment of cancer | |
EP2449383A1 (en) | Diagnostic method for predicting the risk of cancer recurrence based on histone macroh2a isoforms | |
JP2012501440A (ja) | 内分泌処置予測因子としてのanlnタンパク質 | |
US20130295584A1 (en) | Histone protein ubiquitination as a cancer biomarker | |
EP2288721B1 (en) | Treatment prediction involving hmgcr protein | |
US9523690B2 (en) | Biomarkers for the diagnosis and/or prognosis of clear cell renal cell carcinoma | |
US11371995B2 (en) | Method for selecting individuals to be administered immune checkpoint inhibitor | |
US20130095483A1 (en) | Predictive biomarkers for breast cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140808 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150417 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150512 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20150811 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160126 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160223 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5893037 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |